The potential of phytomedicines to optimize CAR-T cell therapy in cancer.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-09-19 DOI:10.1080/1750743X.2025.2555166

Ángela Covo-Vergara, Uxue Díez De Ulzurrun-Ripa, Cristian Smerdou, Mercedes Hernández-Rueda, Delia G Estrada-Palafox, Claudia Ureña, Sandra Hervas-Stubbs, Susana Fiorentino, Maritza R Garcia-Garcia

{"title":"The potential of phytomedicines to optimize CAR-T cell therapy in cancer.","authors":"Ángela Covo-Vergara, Uxue Díez De Ulzurrun-Ripa, Cristian Smerdou, Mercedes Hernández-Rueda, Delia G Estrada-Palafox, Claudia Ureña, Sandra Hervas-Stubbs, Susana Fiorentino, Maritza R Garcia-Garcia","doi":"10.1080/1750743X.2025.2555166","DOIUrl":null,"url":null,"abstract":"<p><p>Immunotherapy has revolutionized oncology therapeutics landscape. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, a form of adoptive cell therapy (ACT) designed to target and kill cancer cells, has shown remarkable success in the treatment of hematological cancer. However, its efficacy against solid tumors remains limited. Phytomedicines represent promising adjuvants to overcome current limitations in cancer immunotherapy due their active compounds that can regulate immune cell functions, modulate immune checkpoint pathways, and reshape the tumoral microenvironment (TME). Current research investigating the TME-modulating effects of certain phytomedicines supports their potential integration as immunotherapy adjuvants. This review focuses on phytomedicines with demonstrated anticancer and immunomodulatory properties, some of which are currently being tested in clinical trials for cancer patients. Despite this promise, significant hurdles persist in the development of phytomedicines as reliable adjuvants in cancer immunotherapy. Consequently, rigorous and focused research is essential to validate their efficacy and safety in this context.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2555166","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Immunotherapy has revolutionized oncology therapeutics landscape. Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, a form of adoptive cell therapy (ACT) designed to target and kill cancer cells, has shown remarkable success in the treatment of hematological cancer. However, its efficacy against solid tumors remains limited. Phytomedicines represent promising adjuvants to overcome current limitations in cancer immunotherapy due their active compounds that can regulate immune cell functions, modulate immune checkpoint pathways, and reshape the tumoral microenvironment (TME). Current research investigating the TME-modulating effects of certain phytomedicines supports their potential integration as immunotherapy adjuvants. This review focuses on phytomedicines with demonstrated anticancer and immunomodulatory properties, some of which are currently being tested in clinical trials for cancer patients. Despite this promise, significant hurdles persist in the development of phytomedicines as reliable adjuvants in cancer immunotherapy. Consequently, rigorous and focused research is essential to validate their efficacy and safety in this context.

查看原文本刊更多论文

植物药物优化CAR-T细胞治疗癌症的潜力。

免疫疗法已经彻底改变了肿瘤治疗领域。嵌合抗原受体t细胞（CAR-T）免疫疗法是一种旨在靶向和杀死癌细胞的过继细胞疗法（ACT），在治疗血液病方面取得了显着的成功。然而，其对实体瘤的疗效仍然有限。植物药是克服当前癌症免疫治疗局限性的有前途的佐剂，因为它们的活性化合物可以调节免疫细胞功能，调节免疫检查点通路，重塑肿瘤微环境（TME）。目前对某些植物药的tme调节作用的研究支持它们作为免疫治疗佐剂的潜在整合。本文综述了具有抗癌和免疫调节特性的植物药物，其中一些药物目前正在癌症患者的临床试验中进行测试。尽管有这样的前景，但在开发植物药作为癌症免疫治疗中可靠的佐剂方面仍然存在重大障碍。因此，在这种情况下，严格和集中的研究对于验证其有效性和安全性至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.